Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Prevnar 13

- PMLiVE

Merck’s Keytruda receives NICE recommendation as breast cancer treatment option

Patients will now be able to access immunotherapy at an earlier stage in their treatment journey

- PMLiVE

Pfizer’s multiple myeloma treatment granted FDA Breakthrough Therapy Designation

Elranatamab-treated patients achieved an overall response rate of 61% in a phase 2 trial

- PMLiVE

Pfizer and BioNTech dose first patient in COVID-19/flu combination vaccine study

The vaccine aims to protect individuals against two severe respiratory viral diseases

- PMLiVE

Pfizer’s maternal RSV vaccine candidate shows promise in phase 3 trial

The company stopped the trial early and plans to file for US approval by the end of 2022

- PMLiVE

Merck to donate Sudan Ebola virus vaccine to International AIDS Vaccine Initiative

Around 50,000 doses are expected to be provided for further clinical research use

- PMLiVE

Merck’s Prevymis shows promise in phase 3 cytomegalovirus disease prevention trial

The drug demonstrated non-inferior efficacy compared to standard of care valganciclovir

- PMLiVE

Merck and Bill & Melinda Gates Institute sign licensing agreement for tuberculosis candidates

The non-profit will determine their potential for inclusion in new affordable treatment regimens

- PMLiVE

Merck and Moderna to jointly develop personalised cancer vaccine in $250m deal

The vaccine is currently being evaluated as a treatment for high-risk melanoma patients

- PMLiVE

Pfizer/BioNTech BA.4/BA.5 COVID-19 booster approved for emergency use by FDA in children five to 11 years

The doses will be shipped immediately, pending recommendation from the CDC

- PMLiVE

Pfizer completes acquisition of Global Blood Therapeutics for $5.4bn

The deal includes a pipeline of sickle cell disease targeted treatments including Oxbryta

- PMLiVE

Pfizer’s Talzenna combination treatment meets primary endpoint in phase 3 prostate cancer study

An improvement in radiographic progression-free survival was demonstrated

- PMLiVE

Pfizer and BioNTech seek FDA authorisation for COVID-19 booster for children

An application will also be submitted to the European Medicines Agency to extend the marketing authorisation for this age group

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links